AHA Scientific Sessions 2023 Late-Breaking Science Coverage

Published: 30 October 2023

  • Views:

    Views Icon 2333
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Stay up-to-date with the latest data in cardiovascular science with the help of renowned experts and emerging voices who offer concise summaries, in-depth discussions, and critical reviews to keep you informed.

 

In their regular View from the Thoraxcenter series, Prof Van Mieghem and Dr Daemen provide valuable insights into the most anticipated trials of AHA 23. With their keen awareness of cardiovascular innovation, they offer concise perspectives on late-breaking data.

 

Dr Harriette Van Spall returns with her Late-breaker Discussion series featuring ground-breaking research presented at Scientific Sessions. Join her and lead investigators as they discuss methodology, results, and impact on patient care.

 

Watch our Expert interviews for late-breaking science methodology, results and implications for practice and research in under 10 minutes.

 

Delve into the personal motivations of some of the investigators, and gain valuable insights and advice for early career researchers in our Behind the Heart series. These short videos offer an opportunity to look beyond scientific achievements and connect on a more personal level.

More from this programme

Part 1

View from the Thoraxcenter

In their regular View from the Thoraxcenter series, Prof Van Mieghem and Dr Daemen provide valuable insights into the most anticipated trials of AHA 23. 

Part 2

Late-Breaker Discussions with Harriette Van Spall

Dr Harriette Van Spall, recipient of 2022's AHA Dr. Nanette K. Wenger Award, returns with her Late-breaker Discussion series featuring ground-breaking research presented at Scientific Sessions. Join her and lead investigators as they discuss methodology, results, and impact on patient care.

About the episode

AHA 23 — Dr Michael Honigberg (Massachusetts General Hospital, US) highlights key 2023 cardiology updates, featuring novel data from AHA Scientific Sessions.

Dr Honigberg  provides commentary on the new SELECT trial outcomes and emphasises the incretin mimetic, semaglutide's role in cardiovascular medicine. He delves into lipid management with a focus on the CLEAR trial data and the incorporation of bempedoic acid into existing treatment paradigms. The CANTOS trial's exploration of colchicine in coronary artery disease patients is another focal point, with Dr Honigberg sharing his experiences integrating it into his therapeutic arsenal.

Furthermore, Dr Honigberg underscores the growing recognition of cardiometabolic health that encourages more holistic approaches to cardiac health. Notably, Dr Honigberg addresses the importance of recognising social determinants of health and advocates for their integration into treatment strategies.

For more content from #AHA23 head to the Late-Breaking or the CardioNerds Conference Scholars Collection.

Recorded on-site at AHA Scientific Sessions 2023, Philadelphia.

Support: This is an independent interview produced by Radcliffe Cardiology.

Editor: Mirjam Boros, Jordan Rance

Videographer: Daniel Brent

Faculty Biographies

Michael Honigberg

Michael Honigberg

Dr Michael Honigberg is a distinguished cardiologist and researcher based at Massachusetts General Hospital and serving as an Assistant Professor of Medicine at Harvard Medical School. With academic excellence from Princeton University, where he graduated summa cum laude and Phi Beta Kappa, he further honed his expertise, earning his MD from Harvard Medical School.

Board-certified in cardiology, echocardiography, and internal medicine, Dr. Honigberg is dedicated to providing comprehensive care for patients grappling with various heart conditions. His focus extends to heart disease prevention and addressing cardiovascular issues in women.

Dr. Honigberg's impactful research employs large cohorts, genetic studies, biomarkers, and advanced imaging techniques. This multifaceted approach aims to unravel unique risk factors for heart disease in women and enhance preventive measures applicable to all. His clinical interests encompass:

  • Cardiovascular…
View full profile

Comments

You must be to comment. If you are not registered, you can register here.